Aaron Sosa Mejia, Vice President, Regulatory Science – Clinical Oncology at Parexel, shared a post on LinkedIn:
“Had been looking forward for this approval based on AZUR-1 for a long time!
Very happy to know most of these patients will be able to spare chemorradiation + surgery +/- colostomy, a true and meaningful innovation in oncology.
Hoping this will be also soon green-lighted by CHMP!”
You can also read: FDA Grants Accelerated Approval: Dostarlimab for MSI-H/dMMR Locally Advanced Rectal Cancer
